These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17427642)

  • 41. Infliximab for patients with neuro-Behcet's disease: case series and literature review.
    Borhani Haghighi A; Safari A; Nazarinia MA; Habibagahi Z; Shenavandeh S
    Clin Rheumatol; 2011 Jul; 30(7):1007-12. PubMed ID: 21431864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and management of intestinal Behçet's disease.
    Hisamatsu T; Naganuma M; Matsuoka K; Kanai T
    Clin J Gastroenterol; 2014 Jun; 7(3):205-12. PubMed ID: 24883128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New approaches in the treatment of Adamantiades-Behçet's disease.
    Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C
    Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of regulatory T cells by infliximab in Behcet's disease.
    Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
    Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
    Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
    Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
    [No Abstract]   [Full Text] [Related]  

  • 48. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
    Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
    Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 50. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
    Ariyachaipanich A; Berkelhammer C; Nicola H
    Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.
    Olivieri I; Padula A; Leccese P; D'Angelo S; Giasi V
    J Rheumatol; 2009 Apr; 36(4):855. PubMed ID: 19342728
    [No Abstract]   [Full Text] [Related]  

  • 53. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H; McGrath H; Espinoza LR
    J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
    Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
    Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful treatment of genital ulcers with infliximab in Behcet's disease.
    Haugeberg G; Velken M; Johnsen V
    Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
    [No Abstract]   [Full Text] [Related]  

  • 57. Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.
    Li Y; Han Z; Wang X; Mo Z; Zhang W; Li A; Liu S
    BMC Gastroenterol; 2013 Dec; 13():167. PubMed ID: 24321021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
    Zlatanović G; Jovanović S; Veselinović D; Zivković M
    Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.